Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. [electronic resource]
Producer: 20190729Description: 1438-1451 p. digitalISSN:- 1528-0020
- Adolescent
- Adult
- Alemtuzumab -- therapeutic use
- Antineoplastic Agents -- therapeutic use
- Child
- Child, Preschool
- Female
- Graft vs Host Disease -- prevention & control
- Hematopoietic Stem Cell Transplantation -- methods
- Humans
- Infant
- Lymphohistiocytosis, Hemophagocytic -- therapy
- Male
- Melphalan -- therapeutic use
- Survival Analysis
- Transplantation Conditioning -- methods
- Treatment Outcome
- Vidarabine -- analogs & derivatives
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural
There are no comments on this title.
Log in to your account to post a comment.